Loading company…
Tokyo-based Orphan Disease Treatment Institute, founded in 2013, develops drugs for Duchenne muscular dystrophy.
Based in Tokyo, Japan, and founded in 2013, Orphan Disease Treatment Institute Co., Ltd researches and develops therapeutic drugs for Duchenne muscular dystrophy. It provides ENA oligonucleotide-based exon skipping induction therapy and is developing the therapeutic agent DS-5141. In March 2023, Daiichi Sankyo acquired the company from INCJ, Ltd. It is at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Orphan Disease Treatment Institute Co., Ltd? This is my company